board members

The Pathology Technology Australia volunteer Board of Directors is made up of recognised leaders across many areas of expertise. They represent the broad diversity of our membership and contribute significant amounts of time, talent, and energy to further the mission of our organisation.

Our Board of Directors has overall responsibility for Pathology Technology Australia's corporate governance. This includes establishing, reviewing and approving the strategic plan, policies, processes, procedures and practices, as well as assessing its own management and performance in order to regularly monitor and assess performance.

The Board of Pathology Technology Australia is elected by the membership from among the Corporate Representatives of Member Companies. Board Members are elected for a 2 year term and appoint a Chair, Deputy-Chair and Treasurer from among their number to serve a 1 year term. More information about the Board of Director’s role and responsibilities can be found in the Pathology Technology Australia Constitution.

Sebastian D’Angelo
Chair, Pathology Technology Australia
General Manager, Laboratory Diagnostics Division, Siemens Healthineers – Australia & New Zealand.

Sebastian has over 30 years’ experience within the Australian IVD industry, having worked as a medical scientist in public pathology laboratories before moving to senior roles at Chiron Diagnostics and Bayer Diagnostics and now at Siemens Healthcare Diagnostics. Sebastian holds a Bachelor of Applied Science (MLS) degree from RMIT University and a Master of Marketing degree from the Melbourne Business School. He is a Member of the Australian Institute of Company Directors.

Karen MacLeod
Deputy Chair, Pathology Technology Australia
Director and Country Manager, MP Biomedicals

Karen’s 30-year career in in the in-vitro diagnostics and pharmaceuticals industries began as a medical scientist in public pathology and includes varied sales and management roles with Australian based global companies such as BioMérieux, Boehringer Mannheim (now Roche) and GSK. Currently Director and Country Manager at MP Biomedicals, she is responsible for all sales, management, and regulatory functions. Karen has a Bachelor of Applied Science and Graduate Diploma in Marketing from UTS, Sydney and has been a member of the IVD Australia Technical and Regulatory Standing Committee since 2011.

Mr Vito Trifilo
Treasurer, Pathology Technology Australia
General Manager, Tecan Australia

I have over 20 years’ experience in the Life Science and in vitro diagnostic businesses in the Australian and New Zealand markets. I have had held business development and sales management roles for over 10 years and was an early company representative with AMRAD Pharmacia Biotech during the start-up phase. My current role is General Manager at Tecan Australia (a position that I have held for over 2 years), with ANZ sales, marketing, legal and regulatory responsibilities. Tecan is a leading global provider of laboratory instruments and solutions (strongly automation focussed) in biopharmaceuticals, forensics and clinical diagnostics.

John Crothers
Chair, Pathology Awareness Australia

Regional Director, Abbott Diagnostics Pty Ltd

John Crothers is the Regional Director for Australia and New Zealand. Prior to the role in Australia, John was the Commercial Director for Asia Pacific and has also had several years in US Marketing. With over 25 years’ experience in the pathology industry in both the laboratory and IVD, the appreciation of the value of the industry in healthcare is a passion that John continues to pursue. John has a BSc(MLS) from RMIT and a Graduate Diploma in Business Administration from Swinburne University.

David Basseal

Business Area Manager, Pathology, Roche Diagnostics Australia Pty Ltd

Tony Feneziani
Head of Research Solutions, Merck

Tony has over 25 years commercial experience in the in vitro diagnostic and life sciences industries. During this time, Tony has undertaken a range of leadership roles including commercial operations, sales and marketing and business development. Tony’s current role at Merck also includes Country Leadership Team membership of the Merck Life Sciences operation in ANZ.

Sally Hickman
General Manager, Werfen Australia & NZ

Sally has over 12 years’ experience in the Australian IVD industry having undertaken key roles in the areas of strategic marketing and customer account management. in 2012, Sally joined Werfen Australia and assumed key management responsibilities at a time when company took direct operations of key business units in Oceania.

Sally has a passion for diagnostics having trained and worked in public pathology laboratories for more than 5 years in the UK. She holds a Bachelor of Science degree in Biomedical Sciences from The University of Bradford, UK and a Master of Science in Biomedical Sciences degree (specialising in Haematology) from The University of Ulster, UK.

Rayden Rivett
General Manager, Cepheid Holdings Pty Ltd

Rayden has been continuously involved in the IVD Industry since 1979 working in sales, marketing and senior management. For 15 years he was Managing Director of bioMérieux in Australia and since 2006 has worked in the USA, Asia-Pacific and more recently in establishing Australian subsidiaries for overseas-based IVD companies. Rayden has represented the IVD sector in the past, being a Board member of MIAA (now MTAA) from 1999 to 2006 and its Vice-Chair (2003-2004), a member of their Diagnostic/IVD Standing Committee 1994-2001, member of the Market Development Committee (1997-2003) and its Chair (2000-2002).

Antoniette Violo
Regional Sales Director, PerkinElmer, Applied Genomics Division

My association with the life sciences, human health and diagnostics industries has extended for over 25 years across the commercial and academic sectors. I am currently the Regional Sales Director for PerkinElmer’s diagnostic’s business in the Applied Genomics division. My commercial career commenced when I was approached to start the Life Sciences Division of PerkinElmer in Australia. I have been fortunate to progress within the organisation and have managed divisions and many staff across Australia, New Zealand and Asia for over 15 years. A significant achievement I am very proud of has been to partner PerkinElmer in the commercialisation of an Australian developed immunoassay kit (TGR Biosciences). I was approached to join the Diagnostics Division twelve months ago to develop the Applied Genomics division within the Asia Pacific region. This has been an exciting challenge and a personal interest of mine in observing the impact that translational medicine has on human health outcomes.